Evidence review
BPC-157 for Long-Term PPI Users
What this covers
Long-term PPI use causes gastric atrophy, B12 deficiency, magnesium depletion, and increased fracture risk. Over 15 million Americans take PPIs daily.
What BPC-157 does
BPC-157 accelerates gastric mucosal healing in rodent models. It protects against NSAID-induced gastric lesions. It modulates NO signaling in the gastric wall.
Evidence grade
- BPC-157 gastric protection: rodent + limited human case reports, moderate quality
- PPI side effects: extensive clinical data, high quality
Practical note
BPC-157 has not been tested in PPI users specifically. The mechanistic rationale for gut lining support exists but is unproven in this population.
Ask this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.
For my medical situation, what can you answer from your catalogue about BPC-157 for Long-Term PPI Users — and what would you need me to tell you first?
ask bpc-157-ppi condition gaps · paste includes §SELF
What good and bad outcomes are documented for BPC-157 for Long-Term PPI Users (studies vs anecdotes)?
ask bpc-157-ppi good bad experiences · paste includes §SELF